Duration of Pain ReliefNCT01756573
Dexamethasone and Block Duration in Upper Extremity
A study testing Dexamthsone and Bupivacaine in people with Duration of Pain Relief, run by University of Chicago at 1 site in United States.
Trial summary
Effect of dexamethasone on prolonging upper extremity block is well known. But it not known if the effect comes from its local effect on the nerves or from its general analgesic effect. In this study we will compare the systemic effect to its local effect to find out if there is a difference or not. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Duration of Pain Relief
- What is being tested?
- Dexamthsone and Bupivacaine
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2013to Jan 2015
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- age 18-75, no contraindication to regional anesthesia,
Who cannot join
- opioid user, chronic pain conditions, peripheral neuropathy
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Chicago Medical Center
Chicago, Illinois, 60637
About this study
Official title: A Study of the Effect of Dexamethasone on Duration of Upper Extremity Blocks With Bupivacaine
Effect of dexamethasone on prolonging upper extremity block is well known. But it not known if the effect comes from its local effect on the nerves or from its general analgesic effect. In this study we will compare the systemic effect to its local effect to find out if there is a difference or not.
- Conditions
- Duration of Pain Relief
- Being tested
- Dexamthsone, Bupivacaine
- Keywords
- block duration, analgesia
- Medical subject headings
- Agnosia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DexamthsoneDrug
BupivacaineDrug
| Study group | Role | What they receive |
|---|---|---|
| Bupivacaine | Active comparator | Control Receives: Drug: Bupivacaine |
| Bupivacaine with Dexamethasone | Experimental | Dexamethasone will be mixed with bupivacaine Receives: Drug: Dexamthsone; Drug: Bupivacaine |
| Intravenous Dexamethasone | Active comparator | Dexamethasone will be given intravenously Receives: Drug: Dexamthsone; Drug: Bupivacaine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Analgesia Duration
Measured: 72 hrs
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Dec 2012 (estimated)
- Study startJan 2013
- Primary completionJan 2015
- Study completionJan 2015
Why it stopped: Unable to continue study due to time constraints
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Duration of Pain ReliefStudies of the same condition, open and under way.
- More trials run by University of ChicagoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Chicago
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Tariq Malik, MD, Principal investigator, University of Chicago
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01756573
- Sponsor's protocol ID
- IRB12-2192
- Status last verified
- Apr 2019
- First submitted
- 20 Dec 2012
- Last updated
- 14 May 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study of the Effect of Dexamethasone on Duration of Upper Extremity Blocks With Bupivacaine
- ClinicalTrials.gov ID
- NCT01756573
- Acronym / sponsor ID
- IRB12-2192
- Conditions
- Duration of Pain Relief
- Keywords
- block duration, analgesia
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Unable to continue study due to time constraints
- Enrolment
- 5 participants (actual)
- Lead sponsor
- University of ChicagoUniversity, hospital or other
- Study start
- Jan 2013
- Primary completion
- Jan 2015 (actual)
- Study completion
- Jan 2015 (actual)
- First posted
- 27 Dec 2012 (estimated)
- Results
- Posted 14 May 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Effect of dexamethasone on prolonging upper extremity block is well known. But it not known if the effect comes from its local effect on the nerves or from its general analgesic effect. In this study we will compare the systemic effect to its local effect to find out if there is a difference or not.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Bupivacaine | Active comparator | Drug: BupivacaineControl |
| Bupivacaine with Dexamethasone | Experimental | Drug: Dexamthsone, Drug: BupivacaineDexamethasone will be mixed with bupivacaine |
| Intravenous Dexamethasone | Active comparator | Drug: Dexamthsone, Drug: BupivacaineDexamethasone will be given intravenously |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- age 18-75, no contraindication to regional anesthesia,
Key exclusion criteria (1 listed)
- opioid user, chronic pain conditions, peripheral neuropathy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dexamthsone | Drug | Bupivacaine with Dexamethasone, Intravenous Dexamethasone |
| Bupivacaine | Drug | Bupivacaine, Bupivacaine with Dexamethasone, Intravenous Dexamethasone |
Primary outcome
Analgesia Duration
Time frame: 72 hrs
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Duration of Pain Relief
Not yet recruitingPhase 4
Post-Operative Spinal Block Duration and Pain Relief After Hip Replacement Surgery: Comparing Single-Shot Spinal Ropivacaine and Bupivacaine
Hip Osteoarthritis, Hip Arthroplasty Replacement
RecruitingObservational study
Time to BBVNA Relief
Low Back Pain, Vertebrogenic Pain Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tariq Malik, MD principal investigator
University of Chicago
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dexamthsone and Bupivacaine in people with Duration of Pain Relief, run by University of Chicago at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 14 May 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 14 May 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Analgesia Duration (time frame: 72 hrs). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2019.